Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 update: The race to therapeutic development
Julianne D. Twomey, Shen Luo, Alexis Q. Dean, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100733-100733
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 262
Emerging SARS-CoV-2 variants of concern and potential intervention approaches
Jasmin Khateeb, Yuchong Li, Haibo Zhang
Critical Care (2021) Vol. 25, Iss. 1
Open Access | Times Cited: 228
Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2
Ashuai Du, Rong Zheng, Cyrollah Disoma, et al.
International Journal of Biological Macromolecules (2021) Vol. 176, pp. 1-12
Open Access | Times Cited: 106
The Mechanism of SARS-CoV-2 Nucleocapsid Protein Recognition by the Human 14-3-3 Proteins
Kristina V. Tugaeva, Dorothy E. D. P. Hawkins, Jake L. R. Smith, et al.
Journal of Molecular Biology (2021) Vol. 433, Iss. 8, pp. 166875-166875
Open Access | Times Cited: 84
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Uttpal Anand, Shweta Jakhmola, Omkar Indari, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 78
Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
Nicola Borbone, Gennaro Piccialli, Giovanni N. Roviello, et al.
Molecules (2021) Vol. 26, Iss. 4, pp. 986-986
Open Access | Times Cited: 69
COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer
Yamin Chen, Luying Cheng, Rongna Lian, et al.
BioScience Trends (2021) Vol. 15, Iss. 2, pp. 64-73
Open Access | Times Cited: 63
SARS-CoV-2 variant trends in Ireland: Wastewater-based epidemiology and clinical surveillance
Liam J. Reynolds, Gabriel González, Laura Sala‐Comorera, et al.
The Science of The Total Environment (2022) Vol. 838, pp. 155828-155828
Open Access | Times Cited: 42
Metabolic Reprogramming in COVID-19
Tao Shen, Tingting Wang
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11475-11475
Open Access | Times Cited: 47
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41
Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection
Hadas Tamir, Sharon Melamed, Noam Erez, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 189-189
Open Access | Times Cited: 29
In Silico Screening of Natural Products Isolated from Mexican Herbal Medicines against COVID-19
Nadia Alejandra Rivero-Segura, Juan Carlos Gómez-Verján
Biomolecules (2021) Vol. 11, Iss. 2, pp. 216-216
Open Access | Times Cited: 34
Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations
Louisa Helms, Silvia Marchianò, Ian B. Stanaway, et al.
JCI Insight (2021) Vol. 6, Iss. 24
Open Access | Times Cited: 33
Marine-Derived Bioactive Metabolites as a Potential Therapeutic Intervention in Managing Viral Diseases: Insights from the SARS-CoV-2 In Silico and Pre-Clinical Studies
Queency N. Okechukwu, Feyisayo O. Adepoju, Osman N. Kanwugu, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 328-328
Open Access | Times Cited: 4
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 4
Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment
Henry Daniell, Smruti K. Nair, Yao Shi, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 266-278
Open Access | Times Cited: 21
When stem cells meet COVID-19: recent advances, challenges and future perspectives
Shasha Li, Hecheng Zhu, Ming Zhao, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
Yi Wang, Sui Fang, Yan Wu, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 4, pp. 781-787
Open Access | Times Cited: 25
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics
Sriram Kumar, Duygu Merve Çalışkan, Josua Janowski, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated review
Saba Zanganeh, Nima Goodarzi, Mohammad Doroudian, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 4
Closed Access | Times Cited: 23
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?
Julian A. Hiscox, Saye Khoo, James P. Stewart, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 9, pp. 2230-2233
Open Access | Times Cited: 22
Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection
Qi Zhang, Peter Radvák, Juhyung Lee, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants
Yan Cheng, Dan Zheng, Derong Zhang, et al.
Journal of Molecular Modeling (2023) Vol. 29, Iss. 4
Open Access | Times Cited: 7
Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies
Nimer Mehyar
Journal of Virus Eradication (2023) Vol. 9, Iss. 2, pp. 100327-100327
Open Access | Times Cited: 6
An Update on Innate Immune Responses during SARS-CoV-2 Infection
Yu Zhang, Shuaiyin Chen, Yuefei Jin, et al.
Viruses (2021) Vol. 13, Iss. 10, pp. 2060-2060
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top